explore -WSS

explore

author：knowledge 2025-10-02 06:40:14 - browse：97

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Biden's 'march

hotspot

WSS

STAT wants to know your pick for a great summer read or listen

STAT wants to know your pick for a great summer read or listen

UnitedHealth CEO's Medicaid comments send insurer stocks diving

A new initiative will help leaders fight the next pandemic

Medicare drug price negotiation continues, as pharma counteroffers

Longer MASH drug regimen improved liver, Akero study finds

leisure time

explore

hotspot

Sports medicine is finally prioritizing gender equality

How CO2 helps viruses stay alive longer in the air

After affirmative action ruling, medical educators look to 'holistic review'

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Sports medicine is finally prioritizing gender equality

Stem cell biologist probes earliest stages of human development

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Guidelines to prevent youth baseball injuries need more muscle

Change Healthcare: What is it, why does its cyberattack matter?

focus

Illumina board agrees to spin off Grail, as divestment plans proceed

$1 billion proposal to grow Boston, Massachusetts biotech

Ancient Greek ideas underpin modern concepts of pregnancy

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

He's 19 months old and has one of the world’s rarest diseases

FTC loses bid to block Novant's North Carolina hospital merger

hotspot

knowledge

focus

Wikipedia